Replimune Group (NASDAQ:REPL) Posts Quarterly Earnings Results, Beats Expectations By $0.24 EPS

Replimune Group (NASDAQ:REPL) issued its quarterly earnings results on Wednesday. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24, FiscalAI reports.

Here are the key takeaways from Replimune Group’s conference call:

• TUDRIQEV’s launch is showing early traction: More than 70% of the initial 200 target accounts have been engaged, approximately 20 have added the drug to formulary, and more than 15 institutions had written prescriptions within the first 20 business days.
• Replimune reported strong physician interest across academic, community, oncology, and interventional radiology settings, with both superficial and image-guided injections already being used. Management expects the number of accounts initiating patients could potentially double by year-end.
• Coverage appears to be broad and favorable: TUDRIQEV has a Category 2A NCCN recommendation, Medicare coverage, and commercial payer policies covering its label—including retreatment in appropriate cases—with a permanent J-code expected by April 2027.
• The company reported no product revenue in the fiscal second quarter because commercial shipments began in October; it will report initial product revenue in the fiscal third quarter but is not providing revenue guidance. TUDRIQEV’s list price is $450,000 per treatment course before discounts, with revenue recognized over multiple quarters in some cases.
• Replimune ended the quarter with $307.8 million in cash, including $141 million from an August offering, and expects funding to support operations for more than 12 months while investing in the launch, IGNYTE-3, and the REVEAL uveal melanoma study.

Replimune Group Stock Down 0.7%

Shares of REPL stock traded down $0.13 during trading hours on Friday, hitting $17.26. 1,134,430 shares of the company’s stock traded hands, compared to its average volume of 4,317,561. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -6.19 and a beta of 0.93. The stock’s fifty day simple moving average is $13.51 and its two-hundred day simple moving average is $9.30. Replimune Group has a 12-month low of $1.50 and a 12-month high of $18.27. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Hill sold 9,256 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the transaction, the chief financial officer owned 215,852 shares of the company’s stock, valued at approximately $3,082,366.56. The trade was a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the transaction, the chief executive officer directly owned 708,151 shares in the company, valued at $9,184,718.47. This represents a 5.26% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock valued at $1,038,364 in the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on REPL. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Finally, Leerink Partners upped their price target on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Replimune Group presently has an average rating of “Moderate Buy” and a consensus target price of $14.33.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.